Stockscreener 앱 받기
15.27
7.23%
-1.19
시간 외 거래:
15.46
0.19
+1.24%
전일 마감가:
$16.46
열려 있는:
$15.83
하루 거래량:
5.49M
Relative Volume:
3.11
시가총액:
$1.59B
수익:
$352.57M
순이익/손실:
$-143.01M
주가수익비율:
-8.4365
EPS:
-1.81
순현금흐름:
$-153.40M
1주 성능:
-31.25%
1개월 성능:
-42.25%
6개월 성능:
-34.77%
1년 성능:
-47.40%
1일 변동 폭
$14.72
$16.66
1주일 범위
$14.72
$21.38
52주 변동 폭
$14.72
$35.25
빔 테라퓨틱스 Stock (BEAM) Company Profile
명칭
Beam Therapeutics Inc
전화
857-327-8775
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
BEAM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
15.27 | 1.59B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
빔 테라퓨틱스 Stock (BEAM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-28 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-10 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-07-23 | 개시 | H.C. Wainwright | Buy |
| 2024-01-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-10-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 개시 | Citigroup | Buy |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-01-05 | 개시 | Guggenheim | Buy |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-09-24 | 재개 | Stifel | Buy |
| 2021-09-10 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Redburn | Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 개시 | Wells Fargo | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-08-05 | 개시 | William Blair | Outperform |
| 2020-03-02 | 개시 | Barclays | Overweight |
| 2020-03-02 | 개시 | JP Morgan | Overweight |
| 2020-03-02 | 개시 | Jefferies | Buy |
| 2020-03-02 | 개시 | Wedbush | Outperform |
모두보기
빔 테라퓨틱스 주식(BEAM)의 최신 뉴스
Beam Therapeutics’ chief legal officer sells $104,121 in stock By Investing.com - Investing.com Canada
Beam Therapeutics’ chief legal officer sells $104,121 in stock - Investing.com India
Beam Therapeutics executive sells $55,330 in stock - Investing.com
Beam Therapeutics president sells $136,418 in stock - Investing.com
Beam Therapeutics Executives Sell Shares for Tax Obligations and Personal Sales - TradingView
Gene Editing: CRISPR Therapeutics vs. Beam Therapeutics - Securities.io
Beam Therapeutics Becomes Oversold - Nasdaq
Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy? - Yahoo Finance
8 Best Gene-Editing Stocks to Buy - Insider Monkey
Biotech stocks plunge as FDA’s Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard - TradingView
Beam Therapeutics’ SWOT analysis: base editing pioneer faces gene therapy hurdles - Investing.com Canada
Beam Therapeutics’ SWOT analysis: base editing pioneer faces gene therapy hurdles By Investing.com - Investing.com South Africa
The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics - Yahoo Finance
BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance - MSN
Beam Therapeutics (BEAM) Upgraded by BofA on Promising Genetic T - GuruFocus
B of A Securities Upgrades Beam Therapeutics (BEAM) - MSN
Beam upgraded to Buy at BofA Securities on recent genetic condition treatment - Seeking Alpha
Beam Therapeutics stock rises after FDA clearance for BEAM-302 IND By Investing.com - Investing.com South Africa
Beam Therapeutics stock rises after FDA clearance for BEAM-302 IND - Investing.com
This Applied Materials Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Benzinga
B of A Securities Upgrades Beam Therapeutics (BMV:BEAM) - Nasdaq
Beyond The Numbers: 9 Analysts Discuss Beam Therapeutics Stock - Benzinga
BofA raises Beam Therapeutics stock rating to Buy, sets $42 target - Investing.com Canada
BofA raises Beam Therapeutics stock rating to Buy, sets $42 target By Investing.com - Investing.com South Africa
BofA Securities Upgrades Beam Therapeutics to Buy From Neutral - Marketscreener.com
FDA Clears Beam Therapeutics' (BEAM) Drug for Genetic Disease Tr - GuruFocus
Beam Therapeutics gets trial authorization for its genetic disorder treatment in U.S. - Seeking Alpha
Beam Therapeutics New Drug Application for Alpha-1 Antitrypsin Deficiency Gets FDA Clearance - Marketscreener.com
Beam Therapeutics’ BEAM-302 gains FDA’s nod for AATD treatment trial - Investing.com India
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration - The Manila Times
Beam Therapeutics’ BEAM-302 gains FDA’s nod for AATD treatment trial By Investing.com - Investing.com Australia
Beam Therapeutics Announces Clearance Of Investigational New Drug Application For BEAM-302 For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD) By The United States (U.S.) Food And Drug Administration - Marketscreener.com
Beam Therapeutics Announces Clearance of Investigational - GlobeNewswire
Breakthrough: FDA Green Lights Beam's Revolutionary Gene Editing Drug for Rare Disease - Stock Titan
Beam Therapeutics (BEAM) Down 21.4% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Beam Therapeutics stock holds firm with $37 target at Bernstein By Investing.com - Investing.com South Africa
Cathie Wood’s ARK focuses on Beam Therapeutics, Intuitive Machines stock - Investing.com
Beam Therapeutics stock holds firm with $37 target at Bernstein - Investing.com
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen - Benzinga
Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy - Seeking Alpha
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN) - The Globe and Mail
Beam Therapeutics’ $500 Million Common Stock Offering - Global Legal Chronicle
Trading (BEAM) With Integrated Risk Controls - Stock Traders Daily
Prime sets sights on liver, lung disease as next target for its gene editing tech - BioPharma Dive
3 Gene Therapy Stocks to Watch Amid Industry Turmoil - Schaeffers Research
Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study - MSN
Is Beam Therapeutics Inc. (BEAM) the Best Growth Stock to Invest in for the Next 10 Years? - Insider Monkey
BEAM Down Despite Positive Initial Data From Genetic Disorder Study - MSN
Wedbush Research Analysts Raise Earnings Estimates for BEAM - Defense World
WilmerHale Advises Beam Therapeutics on $500 Million Underwritten Offering - WilmerHale
Critical Survey: Adaptive Biotechnologies (NASDAQ:ADPT) vs. Beam Therapeutics (NASDAQ:BEAM) - Defense World
빔 테라퓨틱스 (BEAM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
빔 테라퓨틱스 주식 (BEAM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Evans John M. | CEO |
Apr 01 '25 |
Sale |
18.35 |
30,663 |
562,684 |
986,249 |
| Ciaramella Giuseppe | President |
Apr 01 '25 |
Sale |
18.35 |
7,434 |
136,418 |
190,216 |
| Cavanagh Bethany J | SVP, Finance and Treasurer |
Apr 01 '25 |
Sale |
18.35 |
3,015 |
55,330 |
44,512 |
| Simon Amy | Chief Medical Officer |
Apr 02 '25 |
Sale |
17.73 |
20,997 |
372,294 |
65,742 |
| Simon Amy | Chief Medical Officer |
Apr 01 '25 |
Sale |
18.35 |
9,566 |
175,542 |
86,739 |
10.70%
자본화:
|
볼륨(24시간):